Skip to content
Biodatica
Start free

CSPC Ouyi Pharmaceutical Co., Ltd.

Tianjin, Tianjin Municipality

OncologyPhase IIIListed · 1093.HK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients

6d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jul 9, 2026

    Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections, Drug Resistance, Bacterial · NOT_YET_RECRUITING · sponsor: Sizhou Feng · Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients

    ClinicalTrials.gov · NCT07703644 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Mar 15, 2026

    Acute Leukemia, KMT2A Rearrangements or NPM1 Mutations Acute Leukemia · RECRUITING · sponsor: The First Affiliated Hospital of Soochow University · BY002 IIT Study in R/R Acute Leukemia

    ClinicalTrials.gov · NCT07270770 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    May 15, 2025

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation, Avapritinib · RECRUITING · sponsor: The First Affiliated Hospital of Soochow University · A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

    ClinicalTrials.gov · NCT07028073 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Mar 25, 2025

    Mucormycosis in Hematologic Malignancies · RECRUITING · sponsor: Institute of Hematology & Blood Diseases Hospital, China · Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

    ClinicalTrials.gov · NCT07185503 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Mar 30, 2023

    Invasive Candidiasis, Invasive Aspergillosis · COMPLETED · sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. · A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

    ClinicalTrials.gov · NCT05707832 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources